Volume 5 Supplement 1

Proceedings of the 12-th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

MicroRNA analysis in human papillomavirus (HPV)-associated cervical neoplasia and cancer

  • Amy S Gardiner1Email author,
  • William C McBeeJr.2,
  • Robert P Edwards2,
  • Marshall Austin2,
  • Jamie L Lesnock2,
  • Rohit Bhargava3,
  • Richard Guido2 and
  • Saleem A Khan1
Infectious Agents and Cancer20105(Suppl 1):A55

https://doi.org/10.1186/1750-9378-5-S1-A55

Published: 11 October 2010

MicroRNAs (miRNAs) are ~22 nt single-stranded, non-protein-coding RNAs that generally negatively regulate their target mRNAs at a posttranscriptional level. Differential expression of miRNAs has been observed in many human cancers. To study their potential role in the pathogenesis of human papillomavirus (HPV) type 16-associated cervical neoplasia and cancer, we analyzed miRNA expression in cervical tissue from the normal cervix, moderate/severe dysplasia, and invasive squamous cell carcinoma. Using RNA from 6 cervical cancers, 3 dysplasias, and 4 normal samples and the TaqMan® MicroRNA Arrays, we found that 18 miRNAs were overexpressed and 2 underexpressed in cervical cancer compared to the normal cervical tissue (p<0.05). We further found that 9 miRNAs (miRs-16, 21, 106b, 124, 135b, 223, 301b, 449a, and 141) were consistently overexpressed and 2 miRNAs (miRs-218 and 433) were consistently underexpressed in cervical cancer compared to the normal tissue. MiRNA expression in dysplasia samples was most similar to the normal tissue, with the exception of the overexpression of miR-16, miR-141, and miR-449a, and the underexpression of miR-218 and miR-433. Our results suggest that five miRNAs may have potential as markers for progression of dysplasia to invasive cervical disease.

Declarations

Acknowledgements

This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.

Authors’ Affiliations

(1)
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine
(2)
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Women’s Hospital of the University of Pittsburgh Medical Center
(3)
Department of Pathology, Magee-Women’s Hospital of the University of Pittsburgh Medical Center

Copyright

© Gardiner et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement